Abstract: Embodiments of the present invention relates to an X-ray contrast agent. The X-ray contrast agent has an X-ray absorption the change of which between at least two different X-ray photon energy levels differs from the change in X-ray absorption of calcium between the at least two different X-ray photon energy level. Embodiments of the present invention also relates to an X-ray imaging method. Embodiments of the present invention additionally relates to an image reconstruction device. Embodiments of the present invention further relates to an X-ray imaging system.

Abstract: The present invention relates to the technical field of generating artificial contrast-enhanced radiological images.

Abstract: The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as contrast agents in diagnostic imaging, such as in magnetic resonance imaging (MRI) and computed tomography (CT).

Abstract: The present invention relates to pharmaceutical compositions comprising contrast agents, to methods for preparing said pharmaceutical compositions and to their use for radiological imaging.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: A system, method, and computer program product for implementing a remote console for use in diagnostic imaging may include a user interface and/or at least one processor programmed and/or configured to: receive, from at least one of an injection system including an injector configured to deliver fluid to a patient and an imaging system including a scanner configured to scan the patient, procedure data associated with a procedure for the patient, at least one of the injection system and the imaging system including at least one further user interface different than the user interface, and the injection system being in communication with the imaging system; provide, via the user interface, a display, the display being generated based on the procedure data; receive, via the user interface, user input; and control, based on the user input, an operation of at least one of the injection system and the imaging system.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: The present invention relates to systems, methods and computer programs for training and using a machine learning model to generate synthetic contrast-enhanced computed tomography images with the help of magnetic resonance contrast agents.

Abstract: Systems, methods, and computer programs disclosed herein relate to training and using a machine learning model to generate contrast-enhanced magnetic resonance images.

Abstract: Disclosed herein are systems and methods for generating artificial contrast-enhanced computed tomography (CT) images. An exemplary computer-implemented method involves receiving representations of an examination region of an examination object after administration of a contrast agent. The representations result from CT examination of the examination region at different X-ray energies. The method involves generating a representation of the contrast agent signals on the basis of the received representations (e.g., a signal intensity distribution brought about by the contrast agent in the examination region). The method involves generating a synthetic representation of the examination region comprising an ?-fold addition of the representation of the contrast agent signals to one of the received representations or to a virtual non-contrast agent representation of the examination region. ? is a negative or positive real number.

Abstract: The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10- tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: Embodiments of the present invention relates to an X-ray contrast agent. The X-ray contrast agent has an X-ray absorption the change of which between at least two different X-ray photon energy levels differs from the change in X-ray absorption of calcium between the at least two different X-ray photon energy level. Embodiments of the present invention also relates to an X-ray imaging method. Embodiments of the present invention additionally relates to an image reconstruction device. Embodiments of the present invention further relates to an X-ray imaging system.

Abstract: An ensemble of at least two X-ray contrast agents includes X-ray contrast agent and a second X-ray contrast agent. The second X-ray contrast agent has an X-ray absorption whose change between at least two different X-ray photon energies differs significantly from the change of the X-ray absorption of the first X-ray contrast agent between the at least two different X-ray photon energies. An X-ray imaging method, an image reconstruction device, an X-ray imaging system are also disclosed.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation ?W=W2?W1 wherein W1 is a first width of the contrast agent bolus profile at a first vessel position and W2 is a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.